Redhill Biopharma Ltd. ADR (RDHL)
NASDAQ: RDHLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RDHL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.50M
- Forward P/E
- 9.37
- EPS (TTM)
- $0.00
- Dividend yield
- None
- 52-week range
- 0.281 – 1.60
- Day range
- 0.281 – 0.3385
- Volume / Avg
- 24.25K / 2.08M
- Beta
- —
- Shares outstanding
- 8.89M
52-week range
RDHL stock today
Shares of Redhill Biopharma (RDHL) finished lower on Nov 20 at $0.281, a drop of 13.08% or $0.0423 per share, versus the S&P 500's 3.70% decline. Trading was light, with 24.25K shares changing hands, about 1% of the average daily volume. At this level, RDHL sits near the bottom of its 52-week range of $0.281 to $1.60: 82.4% below the high and 0.0% above the low.
Redhill Biopharma has posted a net loss over the last twelve months (EPS of $0.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Redhill Biopharma
Company profileRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Dror Ben-Asher
- Headquarters
- Tel Aviv-Yafo
- Employees
- 13
- Website
- redhillbio.com
Financial highlights
Full financialsIn fiscal 2024, Redhill Biopharma generated $8.0 million in revenue, up 23.2% from fiscal 2023. Redhill Biopharma reported a net loss of $8.3 million, compared with net income of $23.9 million a year earlier. Gross margin was 60.3% (up from 47.0%) and operating margin -181.7%.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $8.04M | $6.53M | $61.80M | $85.76M | $64.36M |
| Growth | +23.17% | -89.43% | -27.94% | +33.25% | +923.03% |
| Net income | $-8.27M | $23.92M | $-71.67M | $-97.74M | $-76.17M |
| EPS (diluted) | $0.00 | $0.01 | $-0.12 | $-0.21 | $-0.21 |
RDHL news
All RDHL newsRedhill Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DRMADermata Therapeutics Inc. | 0.5095 | -4.23% | $2.51M | vs RDHL |
| GRIGRI Bio Inc. | 1.12 | 0.00% | $2.45M | vs RDHL |
| ONCOOnconetix Inc. | 2.89 | -8.54% | $2.37M | vs RDHL |
| HCWBHCW Biologics Inc. | 0.7491 | +1.90% | $2.35M | vs RDHL |
| MBIOMustang Bio Inc. | 0.3541 | -4.30% | $2.69M | vs RDHL |
| TRAWTraws Pharma Inc. | 0.175 | -23.91% | $2.69M | vs RDHL |
| ERNAErnexa Therapeutics Inc. | 1.36 | -16.56% | $2.30M | vs RDHL |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.2449 | +15.03% | $2.19M | vs RDHL |
Indexes, lists and sector
Redhill Biopharma stock FAQ
What is Redhill Biopharma's stock price today?
RDHL last traded at $0.281 as of Nov 20, 4:00 PM EST, down 13.08% on the day. Prices are delayed at least 15 minutes.
Who is Redhill Biopharma's CEO?
Mr. Dror Ben-Asher is the chief executive officer of Redhill Biopharma Ltd. ADR, which has about 13 employees.
What is the RDHL 52-week high?
The 52-week high for RDHL is $1.60 and the 52-week low is $0.281. The stock is currently 82.4% below its high.